Christopher Yea - 21 May 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: CHIEF DEVELOPMENT OFFICER
Issuer ticker: KALV
Reported as of: 21 May 2025
Net transaction value: -$27,516
SEC form: 4
Accepted by SEC: 23 May 2025, 16:25:43 UTC
Prior SEC filing: 20 May 2025
Next SEC filing: 27 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Christopher Yea filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 23 May 2025.

Key facts

This page summarizes Christopher Yea's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 May 2025, 16:25.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: -$27,516.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001691102 Primary reporting owner

Yea Christopher

Relationship: CHIEF DEVELOPMENT OFFICER
Address: C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALV transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,750
Change %: +3.9%
Price
Shares after: 99,307
Date: 21 May 2025
Ownership: Direct
Footnotes: F1

KALV transaction

Common Stock

Sale

Transaction value: $27,516
Shares: -2,317
Change %: -2.3%
Price: $11.88
Shares after: 96,990
Date: 22 May 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALV transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -3,750
Change %: -6.2%
Price: $0.000000
Shares after: 56,250
Date: 21 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,750
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F3

1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.